Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
This strategic collaboration will enable continued innovation in cancer care
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Subscribe To Our Newsletter & Stay Updated
